We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | NASDAQ:BIIB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.70 | 2.66% | 220.11 | 213.50 | 222.00 | 220.21 | 212.90 | 214.625 | 939,980 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the removal of pregnancy contraindications for approved interferon beta treatments for women with relapsing multiple sclerosis, drug makers Biogen Inc. (BIIB) and Merck KGaA (MRK.XE) said Monday.
The companies said the committee issued a positive opinion to update the product label of Biogen's Plegridy and Avonex and Merck's Rebif to include that women with relapsing multiple sclerosis can continue treatment during pregnancy if clinically needed and while breastfeeding.
Merck and Biogen said the CHMP opinion is based on data that indicated no increased risk of major congenital anomalies after pre-conception exposure to interferon beta or exposure during the first trimester of pregnancy, and that levels excreted in breast milk are negligible.
The European Commission generally follows the CHMP's recommendations.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 23, 2019 12:48 ET (16:48 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Biogen Chart |
1 Month Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
